Form 8-K · Current Report · Filed 2026-09-03
AbbVie Completes Acquisition of Apogee Therapeutics
AbbVie Inc. has completed its acquisition of Apogee Therapeutics, Inc. for approximately $10.9 billion in cash. The acquisition, which is expected to negatively impact AbbVie's adjusted diluted earnings per share by $0.14 in 2026 and $0.46 in 2027, aims to strengthen AbbVie's immunology pipeline with new assets targeting dermatologic, respiratory, and other inflammatory diseases. AbbVie reaffirms its 2026 full-year and third-quarter adjusted diluted EPS guidance, which includes the dilutive impact of the acquisition.
- Filer
- AbbVie Inc. ABBV · NYSE
- Filed
- Accession
- 0001104659-26-104940
- CIK
- 0001551152
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$261.71
Since filing
+0.0%
Latest close
$261.71
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ABBV reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, ABBV insiders reported 3 Form 4 transactions — net selling of $5.6M.
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Never miss another ABBV filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.